Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD

被引:167
作者
Pinto-Plata, Victor M.
Livnat, Guy
Girish, Mirle
Cabral, Howard
Masdin, Phil
Linacre, Paul
Dew, Rick
Kenney, Lawrence
Celli, Bartolome R.
机构
[1] Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Pulm & Crit Care Med, Brighton, MA 02135 USA
[2] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA
[3] GlasoSmithKLine, Resp Ctr, Stevenage, Herts, England
[4] GlasoSmithKLine, Human Biomarkers Ctr, Stevenage, Herts, England
关键词
chronic obstuctive lung disease; cytokines; dyspnea; exacerbation;
D O I
10.1378/chest.06-0668
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Background: Systemic inflammation in patients with COPD may worsen during exacerbations, but there is limited information relating levels of systemic inflammatory, markers with symptoms and physiologic changes during an exacerbation Methods: We measured dyspnea using the visual analog scale, pulmonary function tests, hemograms, and plasm levels for interleukin (IL)-6, IL-8, leukotriene B-4 (LTB4), tumor necrosis factor-alpha, and secretory leukocyte protease inhibitor (SLPI) in 20 patients on admission to a hospital for exacerbation of COPD (ECOPD), 48 h later (interim), and 8 weeks after hospital discharge (recovery). Results: Dyspnea was present in all patients. Inspiratory capacity improved faster than FEV1. Compared to recovery, there was a significant increase in the mean (+/- SD) hospital admission plasma levels of IL-6 (6.38 +/- 0.72 to 2.80 +/- 0.79 pg/mL; p = 0.0001), IL-8 (8.18 +/- 0.85 to 3.72 +/- 0.85 pg/mL; p = 0.002), and LTB4 (8,675 +/- 1,652 to 2,534 +/- 1,813 pg/mL; p = 0.003), and the percentages of segmented neutrophils (79 to 69%; p < 0.02) and hand forms (7.3 to 1.0%; p < 0.01) in peripheral blood, with no changes in TNF-alpha and SLPL There were significant correlations between changes in IL-6 (r = 0.61; p = 0.01) and IL-8 (r 0.56; p = 0.04) with changes in dyspnea and levels of IL-6 (r = -0.51; p = 0.04) and TNF-alpha (r -0.71; p < 0.02) with changes in FEV1. Conclusions: Hospitalized patients with ECOPDs experience significant changes in systemic cytokine levels that correlate with symptoms and lung function. An ECOPD represents not only a worsening of airflow obstruction but also increased systemic demand in a host with limited ventilatory reserve.
引用
收藏
页码:37 / 43
页数:7
相关论文
共 33 条
[1]
Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease [J].
Aaron, SD ;
Angel, JB ;
Lunau, M ;
Wright, K ;
Fex, C ;
Le Saux, N ;
Dales, RE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (02) :349-355
[2]
Systemic effects of chronic obstructive pulmonary disease [J].
Agustí, AGN ;
Noguera, A ;
Sauleda, J ;
Sala, E ;
Pons, J ;
Busquets, X .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (02) :347-360
[4]
ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[5]
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J].
Bhowmik, A ;
Seemungal, TAR ;
Sapsford, RJ ;
Wedzicha, JA .
THORAX, 2000, 55 (02) :114-120
[6]
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].
Celli, BR ;
MacNee, W ;
Agusti, A ;
Anzueto, A ;
Berg, B ;
Buist, AS ;
Calverley, PMA ;
Chavannes, N ;
Dillard, T ;
Fahy, B ;
Fein, A ;
Heffner, J ;
Lareau, S ;
Meek, P ;
Martinez, F ;
McNicholas, W ;
Muris, J ;
Austegard, E ;
Pauwels, R ;
Rennard, S ;
Rossi, A ;
Siafakas, N ;
Tiep, B ;
Vestbo, J ;
Wouters, E ;
ZuWallack, R .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946
[7]
VALIDATION OF A COMBINED COMORBIDITY INDEX [J].
CHARLSON, M ;
SZATROWSKI, TP ;
PETERSON, J ;
GOLD, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251
[8]
Cytokines and therapy in COPD - A promising combination? [J].
de Boer, WI .
CHEST, 2002, 121 (05) :209S-218S
[9]
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations [J].
Dentener, MA ;
Creutzberg, EC ;
Schols, AMWJ ;
Mantovani, A ;
van't Veer, C ;
Buurman, WA ;
Wouters, EFM .
THORAX, 2001, 56 (09) :721-726
[10]
Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease [J].
Dev, D ;
Wallace, E ;
Sankaran, R ;
Cunniffe, J ;
Govan, JRW ;
Wathen, CG ;
Emmanuel, FXS .
RESPIRATORY MEDICINE, 1998, 92 (04) :664-667